Macrophages from cancer patients: Analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis

Journal of the National Cancer Institute

Volumn 95, Issue 8, 2003, Pages 611-621

  Herbeuval, Jean Philippe ^a   Lambert, Claude ^a   Sabido, Odile ^a   Cottier, Michèle ^a   Fournel, Pierre ^a   Dy, Michel ^b   Genin, Christian ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; CYTOKINE RECEPTOR; FAS LIGAND; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL ISOLATION; CELL SURFACE; COLON ADENOCARCINOMA; COLON TUMOR; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE ACTIVATION; NICK END LABELING; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

EID: 0038364073     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.8.611     Document Type: Article

References (46)

1. Abe K, Harada M, Tamada K, Ito O, Li T, Nomoto K. Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol Immunother 1998;45:225-33.
2. Koshita Y, Lu Y, Fujii S, Neda H, Matsuyama T, Satoh Y, et al. Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer 1995;63:130-5.
3. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998;64:419-26.
4. Strassmann G, Springer TA, Somers SD, Adams DO. Mechanisms of tumor cell capture by activated macrophages: evidence for involvement of lymphocyte function-associated (LFA)-1 antigen. J Immunol 1986;136: 4328-33.
5. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 1999;28:29-41.
6. Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1998;90: 1648-53.
7. Ishihara Y, Iijima H, Matsunaga K. Contribution of cytokines on the suppression of lung metastasis. Biotherapy 1998;11:267-75.
8. Bonta IL, Ben-Efraim S. Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 1993;54:613-26.
9. Eifuku R, Yoshimatsu T, Yoshino I, Takenoyama M, Imahayashi S, So T, et al. Heterogeneous response patterns of alveolar macrophages from patients with lung cancer by stimulation with interferon-gamma. Jpn J Clin Oncol 2000;30:295-300.
10. Mace KF, Ehrke MJ, Hori K, Maccubbin DL, Mihich E. Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res 1988;48:5427-32.
11. Gruss HJ, Duyster J, Herrmann F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Ann Oncol 1996;7:19-26.
12. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
13. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997;277:768.
14. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
15. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-63.
16. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998;161:2195-200.
17. Golstein P. Cell death: TRAIL and its receptors. Curr Biol 1997;7:R750-3.
18. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
19. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997;416:329-34.
20. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
21. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-20.
22. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
23. Vidalain PO, Azocar O, Lamouille B, Astier A, Rabourdin-Combe C, Servet-Delprat C. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 2000;74:556-9.
24. Strebel A, Bachmann F, Wernli M, Erb P. Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages. Int J Cancer 2002;100:627-34.
25. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
26. Weissflog D, Kroegel C, Luttmann W, Grahmann PR, Hasse J. Leukocyte infiltration and secretion of cytokines in pleural drainage fluid after thoracic surgery: impaired cytokine response in malignancy and postoperative complications. Chest 1999;115:1604-10.
27. Weissler JC, Lipscomb MF, Lem VM, Toews GB. Tumor killing by human alveolar macrophages and blood monocytes. Decreased cytotoxicity of human alveolar macrophages. Am Rev Respir Dis 1986;134:532-7.
28. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Presence and potent immunosuppressive role of interleukin-10 in malignant pleural effusion due to lung cancer. Cancer Lett 1999;136:27-32.
29. Gjomarkaj M, Pace E, Melis M, Spatafora M, Toews GB. Mononuclear cells in exudative malignant pleural effusions. Characterization of pleural phagocytic cells. Chest 1994;106:1042-9.
30. Lombard Y, Giaimis J, Makaya-Kumba M, Fonteneau P, Poindron P. A new method for studying the binding and ingestion of zymosan particles by macrophages. J Immunol Methods 1994;174:155-65.
31. van de Loosdrecht AA, Ossenkoppele GJ, Beelen RH, Broekhoven MG, Drager AM, Langenhuijsen MM. Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis. Exp Hematol 1993;21:1628-39.
32. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-335.
33. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999;93:1456-63.
34. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 1998;161:1983-8.
35. Luschen S, Ussat S, Scherer G, Kabelitz D, Adam-Klages S. Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression. J Biol Chem 2000;275:24670-8.
36. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994;56:777-82.
37. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of turnout necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77:2246-51.
38. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol 1999;15:793-802.
39. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
40. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999;5:146-7.
41. Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 2000;19:3363-71.
42. Glimak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-8.
43. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
44. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-8.
45. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
46. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998;58:1593-8.